This is a summary of the European public assessment report (EPAR) for Multaq. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Multaq. For practical information about using Multaq, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Multaq is indicated for the maintenance of sinus rhythm after successful cardioversion in adult clinically stable patients with paroxysmal or persistent atrial fibrillation (AF). Due to its safety profile, Multaq should only be prescribed after alternative treatment options have been considered. Multaq should not be given to patients with left ventricular systolic dysfunction or to patients with current or previous episodes of heart failure.
Therapeutic Area (MeSH)
N/AATC Code
C01BD07
ATC Item
dronedarone
Pharmacotherapeutic Group
Cardiac therapy
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| dronedarone | N/A | 决奈达隆 |
EMA Name
Multaq
Medicine Name
Multaq
Aliases
N/ANo risk management plan link.
